ArticleFuture science OA2020
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy.
Article in Future science OA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Prognostic role of the baseline neutrophil‒eosinophil ratio in cancer patients: a meta-analysis and systematic review.World journal of surgical oncology · 2025Pooled it
- Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade.Cancer immunology research · 2026Article
- Review
- Immune checkpoint inhibitors and the inflammatory dysregulation: decoding cutaneous and gastrointestinal immune-related adverse events for the allergist and immunologist.Frontiers in immunology · 2026Review
- Eosinophil Dynamics as Prognostic Indicators in Immunotherapy for Pulmonary Lymphoepithelioma-Like Carcinoma.Cureus · 2025Article
- Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma.The oncologist · 2025Article
- Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment.Biomedicines · 2024Article
- Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma.NPJ precision oncology · 2024Article
- Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events.Journal for immunotherapy of cancer · 2024Article
- Eosinophils in Colorectal Cancer: Emerging Insights into Anti-Tumoral Mechanisms and Clinical Implications.International journal of molecular sciences · 2024Review
- The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.Frontiers in immunology · 2024Article
- Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment.Cancers · 2023Review
- Strongyloides-An uncommon cause of eosinophilia whilst on durvalumab.Cancer reports (Hoboken, N.J.) · 2022Article
- The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy.Journal of clinical medicine · 2022Article
- Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma.BMC endocrine disorders · 2022Article
- Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study.Scientific reports · 2022Article
- Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model.PloS one · 2022Article
- PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases.Frontiers in pharmacology · 2022Review
- Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.Cancer management and research · 2022Article
- Tumor-associated eosinophilia in a patient withTranslational cancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate eosinophilia as a potential on-treatment biomarker for patients receiving cancer immunotherapy. MATERIALS &
methodsWe evaluated the association between eosinophilia and treatment response and toxicity in a retrospective cohort of patients receiving cancer immunotherapy.
resultsThe study involved 146 patients. Eosinophilia developed in 22%. Patients who developed eosinophilia were more likely to achieve disease control (p = 0.009), with every 0.1 × 10
conclusionEosinophilia is a potentially useful biomarker warranting further prospective clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.